Notice Number: NOT-CA-05-003
Release Date: October 26, 2004
The NATIONAL CANCER INSTITUTE (NCI) is requesting applications for the following initiative: Rapid Access to Intervention Development (RAID). RAID will make available to academic investigators, on a competitive basis, the preclinical development contract resources of NCI's Developmental Therapeutics Program (DTP). RAID is not a grant program. Approved applications to RAID instead gain access to the drug development contract resources of the Developmental Therapeutics Program. The goal of RAID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for proof-of-principle clinical trials. RAID will assist investigators who submit successful applications by providing any (or all) of the preclinical development steps that may be obstacles to clinical translation. Possible tasks may include production, bulk supply, good manufacturing process (GMP) manufacturing, formulation, and toxicology. Suitable agents for RAID will include small molecules, biologics, or vaccines.
There are two receipt dates, February 1 and August 1, for requests for RAID support per year. Starting with the February 1, 2005 application cycle, investigators must submit a 1-2 page letter-of- intent summarizing the proposed project at least 15 days before the deadline. Full applications must be received by February 1, 2005, with all materials submitted directly to the office listed below.
For information on the procedure for requesting RAID resources, visit the DTP web site http://dtp.nci.nih.gov/ . Inquiries are encouraged, and DTP staff welcomes opportunities to clarify issues or answer questions about the RAID program. Academic investigators may have collaborations with small-business partners and still qualify for RAID funding. Non-profit organizations other than universities may also submit RAID applications. Please note that a maximum of two distinct requests for support per investigator can be submitted for each receipt date.
Inquiries regarding this notice may be directed to:
Office of Associate Director
Developmental Therapeutics Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Blvd., EPN Suite 8022
Bethesda, MD 20892 (U.S. mail)
Rockville, MD 20852 (for express/courier service)
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.